138 related articles for article (PubMed ID: 3322924)
41. [Possibilities of the use of present-day antisecretory preparation omeprazole].
Degtiareva II; Semeunovich S; Kharchenko NV; Petrovich S; Gaĭsenko AV; Egorova IT
Klin Med (Mosk); 1994; 72(6):38-40. PubMed ID: 7898006
[No Abstract] [Full Text] [Related]
42. Lansoprazole.
Med Lett Drugs Ther; 1995 Jul; 37(953):63-4. PubMed ID: 7603391
[No Abstract] [Full Text] [Related]
43. [Risk for developing tumors in therapy with the proton pump inhibitor omeprazole].
Eissele R; Arnold R
Versicherungsmedizin; 1993 Aug; 45(4):126-9. PubMed ID: 8379045
[TBL] [Abstract][Full Text] [Related]
44. Hemolytic anemia associated with the use of omeprazole.
Marks DR; Joy JV; Bonheim NA
Am J Gastroenterol; 1991 Feb; 86(2):217-8. PubMed ID: 1992636
[TBL] [Abstract][Full Text] [Related]
45. [Omeprazole and inhibition of gastric acid secretion].
Rossi G
Recenti Prog Med; 1984 Apr; 75(4):419-21. PubMed ID: 6729204
[No Abstract] [Full Text] [Related]
46. [Reply to the critique by Drs. Díaz de Rojas y Castelló Tapias].
Cataldi R; Meeroff M
Rev Esp Enferm Dig; 1991 Oct; 80(4):285-6. PubMed ID: 1805899
[No Abstract] [Full Text] [Related]
47. [Cimetidine or ranitidine?].
Lamers CB
Ned Tijdschr Geneeskd; 1986 Apr; 130(16):716-9. PubMed ID: 3012376
[No Abstract] [Full Text] [Related]
48. Investigation into the role of cephalic stimulation of acid secretion on gastric emptying and appetite following a soup meal using the gastric acid inhibitor omeprazole.
Cecil JE; Francis J; Read NW
Appetite; 2004 Feb; 42(1):99-105. PubMed ID: 15036788
[TBL] [Abstract][Full Text] [Related]
49. [Recent developments in drugs antagonistic to factors causing peptic ulcer--clinical efficacy and problems; gastric mucosa proton pump inhibitors].
Okabe S; Akimoto Y
Nihon Rinsho; 1988 Jan; 46(1):33-8. PubMed ID: 2836641
[No Abstract] [Full Text] [Related]
50. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects.
Kim HK; Park SH; Cheung DY; Cho YS; Kim JI; Kim SS; Chae HS; Kim JK; Chung IS
J Gastroenterol Hepatol; 2010 Oct; 25(10):1618-25. PubMed ID: 20880169
[TBL] [Abstract][Full Text] [Related]
51. [H2 receptor blockaders: domains for oral use. Indications for cimetidine and ranitidine in gastroenterology].
Hotz J
Fortschr Med; 1984 Feb; 102(8):203-4. PubMed ID: 6086477
[No Abstract] [Full Text] [Related]
52. Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study.
Moretzsohn LD; Carvalho EB; Franco JD; Soares MP; Brito EM; Belarmino K; Coelho LG
Can J Clin Pharmacol; 2009; 16(1):e264-72. PubMed ID: 19383986
[TBL] [Abstract][Full Text] [Related]
53. [Lansoprazol ++ : a new proton pump inhibitor].
Baczek J; Laskowiec G
Pol Merkur Lekarski; 1998 Jun; 4(24):339-41. PubMed ID: 9771021
[TBL] [Abstract][Full Text] [Related]
54. Omeprazole and reflux oesophagitis.
Kerr GD
Aliment Pharmacol Ther; 1994 Apr; 8(2):263. PubMed ID: 8038359
[No Abstract] [Full Text] [Related]
55. [Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999].
Dobrilla G; Capurso L
Recenti Prog Med; 2000 Apr; 91(4):191-210. PubMed ID: 10804753
[TBL] [Abstract][Full Text] [Related]
56. Drug therapy of peptic ulcer disease.
Ching CK; Lam SK
Br J Hosp Med; 1995 Jul 12-Aug 15; 54(2-3):101-6. PubMed ID: 7551483
[TBL] [Abstract][Full Text] [Related]
57. [Reduced ex vivo production of superoxide anion by polymorphonuclear leukocytes during therapy with omeprazole. A pharmacological effect?].
Capodicasa E; Ciaccio V; Corazzi F; De Bellis F; Bucaneve G; Ficola F; Pelli MA
Minerva Gastroenterol Dietol; 1994 Sep; 40(3):105-11. PubMed ID: 7948319
[TBL] [Abstract][Full Text] [Related]
58. [Losek (omeprazole), a new therapeutic agent in the treatment of peptic ulcer and hyperacidity states].
Bulgakov SA
Klin Med (Mosk); 1995; 73(5):11-6. PubMed ID: 8815266
[No Abstract] [Full Text] [Related]
59. [Omeprazole in peptic ulcer--pros and cons].
Stasiewicz J
Wiad Lek; 1986 Jun; 39(11):765-71. PubMed ID: 3535259
[No Abstract] [Full Text] [Related]
60. Omeprazole treatment of severe peptic disease associated with antral G cell hyperfunction and hyperpepsinogenemia I in an infant.
De Giacomo C; Fiocca R; Villani L; Licardi G; Scotta MS; Solcia E
J Pediatr; 1990 Dec; 117(6):989-93. PubMed ID: 2246706
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
